https://nova.newcastle.edu.au/vital/access/ /manager/Index ${session.getAttribute("locale")} 5 https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:26131 Wed 11 Apr 2018 14:53:18 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:36736 Thu 02 Jul 2020 16:31:45 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:19533 95% of the identified indication bias. Slightly lower relapse incidence was found among patients treated with glatiramer acetate or subcutaneous interferon β-1a relative to intramuscular interferon β-1a and interferon β-1b (p≤0.001). No differences in 12-month confirmed progression of disability were observed. Conclusion: Small but statistically significant differences in relapse outcomes exist among the injectable immunomodulators. MSBase is sufficiently powered to identify these differences and reflects practice in tertiary MS centres. While the present study controlled indication, selection and attrition bias, centre-dependent variance in data quality was likely.]]> Sat 24 Mar 2018 08:02:06 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:29000 Sat 24 Mar 2018 07:41:17 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:22288 Sat 24 Mar 2018 07:17:30 AEDT ]]>